DEBA PHARMA
ActiveSummary
DEBA PHARMA has been active since 1988 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.2m and a net result of €2.1m. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 94% of 88 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
06-10
Gazette deed
Reappointments: Johan DEJONGHE, INFICOM BV and 3 othersPermanent representative: Ingrid BAEKELANDT9 facts ▸
- General meeting, 30-06-2025
- Director reappointment, Johan DEJONGHE (director)
- Director reappointment, INFICOM BV (director)
- Permanent representative, Ingrid BAEKELANDT
- Director reappointment, Kristof DEJONGHE (director)
- Director reappointment, Vincent DEJONGHE (director)
- Director reappointment, Frederik DEJONGHE (director)
- Board meeting, 30-06-2025
- Director reappointment, Johan DEJONGHE (managing director)
About the unread acts
Of the 10 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 9 have not been read yet: what they contain is neither established nor disproved here.